|
|
Volumn 10, Issue 12, 2011, Pages 885-887
|
|
Success of immunomodulators in MS shifts discovery focus to neuroprotection
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEMTUZUMAB;
BETA1A INTERFERON;
BIIB 033;
DACLIZUMAB;
FINGOLIMOD;
FUMARIC ACID DIMETHYL ESTER;
GLATIRAMER;
GSK 1223249;
IMMUNOMODULATING AGENT;
LAQUINIMOD;
MONOCLONAL ANTIBODY;
MYELIN;
OCRELIZUMAB;
TERIFLUNOMIDE;
UNCLASSIFIED DRUG;
AMYOTROPHIC LATERAL SCLEROSIS;
ARTICLE;
BLOOD BRAIN BARRIER;
CHRONIC LYMPHATIC LEUKEMIA;
DIARRHEA;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG RESEARCH;
DRUG SAFETY;
FLUSHING;
GENETIC SUSCEPTIBILITY;
HUMAN;
IMMUNOMODULATION;
MULTIPLE SCLEROSIS;
NERVE DEGENERATION;
NERVE FIBER DEGENERATION;
NEUROPROTECTION;
NONHUMAN;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
POSITRON EMISSION TOMOGRAPHY;
PRIORITY JOURNAL;
REMYELINIZATION;
SIDE EFFECT;
SIGNAL TRANSDUCTION;
CLINICAL TRIALS, PHASE II AS TOPIC;
CLINICAL TRIALS, PHASE III AS TOPIC;
DRUG DISCOVERY;
HUMANS;
IMMUNOLOGIC FACTORS;
MULTIPLE SCLEROSIS, RELAPSING-REMITTING;
NEUROPROTECTIVE AGENTS;
|
|
EID: 82455212646
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3610 Document Type: Article |
|
Times cited : (9)
|
|
References (0)
|
